FDA authorizes AI-driven MRI Solution for Safer Alzheimer’s Treatment
Imaging Technology
NOVEMBER 18, 2024
A large study, needed for FDA clearance, demonstrated that the use of icobrain aria significantly increases the accuracy of ARIA assessments by radiologists and hence allows for safer use of new amyloid-beta targeting therapies for Alzheimer’s disease patients. icobrain aria was thoroughly evaluated in large reader studies.
Let's personalize your content